J. E. Davis sold $6.6M of DGX
CEO and President at QUEST DIAGNOSTICS INC. 39,191 shares at an average of $168.46, traded Apr 2, 2025, filed Apr 4, 2025.
Score components
- +25RoleCEO
- +25Trade size$6.6M at market
- +5Share of holdings soldSold 23% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001022079-25-000109, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -2,366 | $168.03 | $398k | 164,448 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -1,411 | $168.76 | $238k | 163,037 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -704 | $169.63 | $119k | 162,333 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -7,249 | $167.86 | $1.2M | 155,084 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -4,905 | $168.72 | $828k | 150,179 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -2,764 | $169.56 | $469k | 147,415 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -6,950 | $167.86 | $1.2M | 140,465 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -5,900 | $168.66 | $995k | 134,565 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -2,493 | $169.57 | $423k | 132,072 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -750 | $167.86 | $126k | 131,322 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -584 | $168.70 | $99k | 130,738 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -267 | $169.60 | $45k | 130,471 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -1,493 | $167.88 | $251k | 128,978 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -902 | $168.79 | $152k | 128,076 | Apr 4, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -453 | $169.63 | $77k | 127,623 | Apr 4, 2025 |
Related signals
Other insiders at QUEST DIAGNOSTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | QUEST DIAGNOSTICS INC | J. E. Davis CEO and President | $2.4M 10,000 shares | -8% | |
| 40Moderate | QUEST DIAGNOSTICS INC | J. E. Davis CEO and President | $11M 55,093 shares | -31% | |
| 43Moderate | QUEST DIAGNOSTICS INC | Vicky B Gregg director | $240k 1,250 shares | -7% | |
| 40Moderate | QUEST DIAGNOSTICS INC | Mark E Delaney SVP & Chief Commercial Officer | $1.5M 7,946 shares | -51% | |
| 0Weak | QUEST DIAGNOSTICS INC | Michael E Prevoznik SVP & General Counsel | $43k 227 shares | -1% | |
| 15Weak | QUEST DIAGNOSTICS INC | Michael E Prevoznik SVP & General Counsel | $5.3M 28,463 shares | -43% | |
| 15Weak | QUEST DIAGNOSTICS INC | Patrick Plewman SVP for Diagnostic Services | $365k 1,975 shares | -11% | |
| 8Weak | QUEST DIAGNOSTICS INC | Patrick Plewman SVP for Diagnostic Services | $829k 4,532 shares | -21% | |
| 15Weak | QUEST DIAGNOSTICS INC | Patrick Plewman SVP for Diagnostic Services | $356k 1,975 shares | -10% | |
| 18Weak | QUEST DIAGNOSTICS INC | Patrick Plewman SVP for Diagnostic Services | $969k 5,535 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.